Cited by 253Protein Degradation and InhibitorsCytokine Signaling Pathways and InteractionsChemical Synthesis and Analysis

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Open access

Zhou, Haibin, Bai, Longchuan, Xu, Renqi, Zhao, Yujun, Chen, Jianyong, McEachern, Donna, Chinnaswamy, Krishnapriya, Wen, Bo, Dai, Lipeng, Kumar, Praveen, Yang, Chao-Yie, Liu, Zhaomin, Wang, Mi, Liu, Liu, Meagher, Jennifer L., Yi, Han, Sun, Duxin, Stuckey, Jeanne A., Wang, Shaomeng·2019·Journal of Medicinal Chemistry

DOI 10.1021/acs.jmedchem.9b01530PMC PMC8848307

Open this paper in CoChat — free account

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b01530

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery
Vilar, S., Cozza, G., & Moro, S. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786786624 · Cited by 1,200

Show all 40 references

Research works printed but not linked: 2

Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version, 2.10.3; Global Phasing Ltd.: Cambridge, U.K., 2017.
Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G. GRADE, version 1.2.13; Global Phasing Ltd.: Cambridge, U.K., 2017.

Sorted by citations

Targeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 1,035
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Li, X., & Song, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00885-3 · Cited by 559
Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
Ouyang, S., Li, H., Lou, L., Huang, Q., Zhang, Z., Mo, J., Li, M., Lu, J., Zhu, K., Chu, Y., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102317 · Cited by 517
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S., Dong, J., Xu, Z., Cheng, X., Zhang, W., & Qin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 306
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 264
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene · doi:10.1038/s41388-020-1336-y · Cited by 252
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Bemis, T. A., Clair, J. J. L., & Burkart, M. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00482 · Cited by 250
Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Dong, J., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00629 · Cited by 232
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
Moskowitz, A. J., Ghione, P., Jacobsen, E. D., Ruan, J., Schatz, J. H., Noor, S. J., Myskowski, P. L., Vardhana, S. A., Ganesan, N., Hancock, H., et al. (2021) · Blood · doi:10.1182/blood.2021013379 · Cited by 192
Self-citation
PROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 192
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 176
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172
Self-citation
The state of the art of PROTAC technologies for drug discovery
Wang, C., Zheng, C., Wang, H., Zhang, L., Liu, Z., & Xu, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114290 · Cited by 129
Self-citation
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Fang, Y., Wang, S., Han, S., Zhao, Y., Yu, C., Liu, H., & Li, N. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.003 · Cited by 113
Self-citation
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 112
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
Mohrherr, J., Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · Cancers · doi:10.3390/cancers12051107 · Cited by 107
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Yang, J., Chang, Y., Tien, J. C.-Y., Wang, Z., Zhou, Y., Zhang, P., Huang, W., Vo, J. N., Apel, I. J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00384 · Cited by 99
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Bhansali, R. S., Rammohan, M., Lee, P., Laurent, A. P., Wen, Q., Suraneni, P. K., Yip, B. H., Tsai, Y.-C., Jenni, S., Bornhauser, B. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135937 · Cited by 98
Targeting NRF2 to treat cancer
Sivinski, J., Zhang, D. D., & Chapman, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.003 · Cited by 94
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Han, X., & Sun, Y. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101062 · Cited by 89
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo
Luo, G., Li, Z., Lin, X., Li, X., Chen, Y., Xi, K., Xiao, M., Wei, H., Zhu, L., & Xiang, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.001 · Cited by 84
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 88
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Yang, X., Wang, Z., Pei, Y., Song, N., Xu, L., Feng, B., Wang, H., Luo, X., Hu, X., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113341 · Cited by 85
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
Chang, Y., Min, J., Jarusiewicz, J., Actis, M., Bradford, S. Y. C., Mayasundari, A., Yang, L., Chepyala, D., Alcock, L. J., Roberts, K. G., et al. (2021) · Blood · doi:10.1182/blood.2020006846 · Cited by 80
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 83
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Kaneshige, A., Bai, L., Wang, M., McEachern, D., Meagher, J. L., Xu, R., Wang, Y., Jiang, W., Metwally, H., Kirchhoff, P. D., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01248-4 · Cited by 74
Self-citation
Deregulated transcription factors in cancer cell metabolisms and reprogramming
Kant, R., Manne, R., Anas, M., Penugurti, V., Chen, T., Pan, B., Hsu, C.-C., & Lin, H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.001 · Cited by 76
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 72
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Mostofian, B., Martin, H., Razavi, A. M., Patel, S., Allen, B. K., Sherman, W., & Izaguirre, J. A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00603 · Cited by 70
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Han, X., Wei, W., & Sun, Y. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0010 · Cited by 70
Targeting androgen receptor degradation with PROTACs from bench to bedside
Jia, X., & Han, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114112 · Cited by 68
The rise of degrader drugs
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 63
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 68
Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91
Hanafi, M., Chen, X., & Neamati, N. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01897 · Cited by 61
E3 ligase ligand optimization of Clinical PROTACs
Jiang, H., Xiong, H., Gu, S.-X., & Wang, M. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1098331 · Cited by 64
Self-citation
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
Thomas, J. E., Wang, M., Jiang, W., Wang, M., Wang, L., Wen, B., Sun, D., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00492 · Cited by 60
Self-citation
Discovery of a PROTAC targeting ALK with in vivo activity
Yan, G., Zhong, X.-X., Lin, Y., Pu, C., Shan, H., Lan, S., Zhou, M., Hou, X., Yang, J., & Li, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113150 · Cited by 59
Taking Aim at the Undruggable
Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 59
Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
Jin, J., Wu, Y., Zhao, Z., Wu, Y., Zhou, Y.-D., Liu, S., Sun, Q., Yang, G., Lin, J., Nagle, D. G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160606 · Cited by 57
“The application of PROTACs has afforded several advantages for targeting STAT3 over traditional inhibitors (26, 49).”
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Chen, Q., Liu, C., Wang, W., Meng, X., Cheng, X., Li, X.-Y., Cai, L., Luo, L., He, X., Qu, H., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00797 · Cited by 55
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Zhou, H., Bai, L., Xu, R., McEachern, D., Chinnaswamy, K., Li, R., Wen, B., Wang, M., Yang, C., Meagher, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00155 · Cited by 56
Self-citation
Nucleic-Acid-Based Targeted Degradation in Drug Discovery
Wang, W., He, S., Dong, G., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00875 · Cited by 56
Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives
Song, J., Wang, J., Tian, S., & Li, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819093117 · Cited by 54
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 49
AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss
Hati, S., Zallocchi, M., Hazlitt, R. A., Li, Y., Vijayakumar, S., Min, J., Ranković, Z., Lovas, S., & Zuo, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113849 · Cited by 46
Selectivity through Targeted Protein Degradation (TPD)
Gopalsamy, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00397 · Cited by 45
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Ni, Y., Low, J. T., Silke, J., & O’Reilly, L. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835997 · Cited by 47
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia
Kaneshige, A., Bai, L., Wang, M., McEachern, D., Meagher, J. L., Xu, R., Kirchhoff, P. D., Wen, B., Sun, D., Stuckey, J. A., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01665 · Cited by 46
Self-citation
Small molecule drug discovery targeting the JAK-STAT pathway
Lv, Y., Mi, P., Babon, J. J., Fan, G.-H., Qi, J., Cao, L., Lang, J., Zhang, J., Wang, F., & Kobe, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107217 · Cited by 48
Targeting the STAT3 pathway with STAT3 degraders
Wang, Z., Liao, X., He, H., Guo, X., & Chen, J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.07.003 · Cited by 46
Self-citation
Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities
Song, R., Qiao, W., He, J., Huang, J., Luo, Y., & Yang, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01640 · Cited by 45
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Nielsen, O. H., Boye, T. L., Gubatan, J. M. B., Chakravarti, D., Jaquith, J. B., & LaCasse, E. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108402 · Cited by 44
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 45
PROTACs: New method to degrade transcription regulating proteins
Hu, B.-C., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 43
Self-citation
Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors
Brotherton‐Pleiss, C., Yue, P., Zhu, Y., Nakamura, K., Chen, W., Fu, W., Kubota, C. S., Chen, J., Alonso-Valenteen, F., Mikhael, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01705 · Cited by 43
Self-citation
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 42
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 42
Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery
Elhassan, R. M., Hou, X., & Fang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21871 · Cited by 40
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Cieślak, M., & Słowianek, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030812 · Cited by 42
Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2
Shaheer, M., Singh, R., & Sobhia, M. E. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1953601 · Cited by 40
Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)
Kang, Z., Shen, L., Li, Y., Song, J., Peng, Y., & Chen, Y. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110447 · Cited by 42
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation
Jung, H., & Lee, Y. (2025) · Cancers · doi:10.3390/cancers17111871 · Cited by 41
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 48
Self-citation
Targeting SHP2 as a therapeutic strategy for inflammatory diseases
Liu, Y., Yang, X., Wang, Y., Yang, Y., Sun, D., Li, H., & Chen, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113264 · Cited by 40
Self-citation
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy
Zeng, L., Zhu, Y., Moreno, C. S., & Wan, Y. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.003 · Cited by 38
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 38
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3
Hall, J., Zhang, Z., Bhattacharya, S., Wang, D., Alcantara, M. B., Liang, Y., Swiderski, P. M., Forman, S. J., Kwak, L. W., Vaidehi, N., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102137 · Cited by 39
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 37
Self-citation
Targeted protein degradation: current molecular targets, localization, and strategies
Pliatsika, D., Blatter, C., & Riedl, R. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104178 · Cited by 40
Targeted Protein Degradation: Design Considerations for PROTAC Development
Tran, N. L., Leconte, G. A., & Ferguson, F. M. (2022) · Current Protocols · doi:10.1002/cpz1.611 · Cited by 35
Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity
Hu, J., Hu, B., Xu, F., Wang, M., Qin, C., McEachern, D., Stuckey, J. A., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00520 · Cited by 36
Self-citation
Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment
He, P., Bian, A., Miao, Y., Jin, W., Chen, H., He, J., Li, L., Sun, Y., Ye, J., Liu, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01554 · Cited by 34
Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes
Dankner, M., Maritan, S. M., Priego, N., Kruck, G., Nkili-Meyong, A. A., Nadaf, J., Zhuang, R., Annis, M. G., Zuo, D., Nowakowski, A., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae013 · Cited by 34
The Ubiquitin–Proteasome System in Tumor Metabolism
Wang, J., Xiang, Y., Fan, M., Fang, S., & Hua, Q. (2023) · Cancers · doi:10.3390/cancers15082385 · Cited by 32
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
Malarvannan, M., Unnikrishnan, S., Monohar, S., Ravichandiran, V., & Paul, D. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107984 · Cited by 34
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
Shiah, J. V., Grandis, J. R., & Johnson, D. E. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0599 · Cited by 32
A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer
Chou, P.-H., Luo, C.-K., Wali, N., Lin, W.-Y., Ng, S.-K., Wang, C., Zhao, M., Lin, S., Yang, P., Liu, P.-J., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00803-4 · Cited by 35
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Xu, R., Zhou, H., Bai, L., McEachern, D., Wu, D., Acharyya, R. K., Wang, M., Tošović, J., Yang, C., Chinnaswamy, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01946 · Cited by 31
Self-citation
Palladium-catalyzed [4 + 3] dearomatizing cycloaddition reaction of N -iminoquinolinium ylides
Dai, W., Li, C., Liu, Y., Han, X., Li, X., Chen, K., & Liu, H. S. (2020) · Organic Chemistry Frontiers · doi:10.1039/d0qo00320d · Cited by 31
Recent advances in synthetic and medicinal chemistry of phosphotyrosine and phosphonate-based phosphotyrosine analogues
Makukhin, N., & Ciulli, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00272k · Cited by 31
Altered pathways and targeted therapy in double hit lymphoma
Zhuang, Y., Che, J., Wu, M., Guo, Y. L., Xu, Y., Dong, X., & Yang, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01249-9 · Cited by 31
Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis
Jin, W., Zhang, T., Zhou, W., He, P., Sun, Y., Hu, S., Chen, H., Ma, X., Peng, Y., Yi, Z., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00004 · Cited by 30
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo
Mi, D., Cheng, L., Li, Y., Yao, M., Li, Y., Hong, K., Xie, C., & Chen, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116789 · Cited by 32
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
Kaneshige, A., Yang, Y., Bai, L., Wang, M., Xu, R., Mallik, L., Chinnaswamy, K., Metwally, H., Wang, Y., McEachern, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01009 · Cited by 31
Self-citation
Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy
Feng, K.-R., Wang, F., Shi, X., Tan, Y., Zhao, J., Zhang, J., Li, Q., Lin, G., Gao, D., & Tian, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112428 · Cited by 29
Small-Molecule PROTACs for Cancer Immunotherapy
Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 30
Self-citation
Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment
He, P., Miao, Y., Sun, Y., Bian, A., Jin, W., Chen, H., Ye, J., He, J., Peng, Y., Gu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00413 · Cited by 29
The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
Zeng, S., Zhang, H., Shen, Z., & Huang, W. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.639176 · Cited by 26

Authors: Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., Yang, C.-Y., Liu, Z., Wang, M., Liu, L., Meagher, J. L., Yi, H., Sun, D., Stuckey, J. A., & Wang, S.
Affiliations: University of Michigan (US)
Corresponding author: Wang, Shaomeng
ORCID: Zhou, Haibin
Bai, Longchuan
Zhao, Yujun
Chen, Jianyong
McEachern, Donna
Wen, Bo
Kumar, Praveen
Yang, Chao-Yie
Liu, Zhaomin
Wang, Mi
Liu, Liu
Meagher, Jennifer L.
Sun, Duxin
Stuckey, Jeanne A.
Wang, Shaomeng
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2019-11-20
Volume: 62
Issue: 24
Pages: 11280-11300
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.9b01530
PMC: PMC8848307
OpenAlex: W2990256176
Cited by: 233
References: 40
Citations by year: 2026: 26 · 2025: 43 · 2024: 31 · 2023: 33 · 2022: 44 · 2021: 28 · 2020: 27
FWCI: 8.85
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-045 (stm-asf)
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30 CA046592)
Comprehensive Cancer Center, University of Michigan
Oncopia Therapeutics Inc.
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: STAT3, PROTACs, small-molecule degraders, SH2 domain inhibitors, structure-based drug design, leukemia, lymphoma, xenograft tumor regression, protein degradation
MeSH terms: Animals, Antineoplastic Agents, Azocines, Female, Humans, Indoles, Protein Conformation, Tissue Distribution, Tumor Cells, Cultured, Drug Design, Molecular Structure, Leukemia, Myeloid, Acute, Mice, SCID, Apoptosis, Xenograft Model Antitumor Assays, Cell Proliferation, STAT3 Transcription Factor, Mice, Drug Discovery, Proteolysis, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks